Lumpectomy Plus Tamoxifen or Anastrozole With or Without Whole Breast Irradiation in Women With Favorable Early Breast Cancer
- Departments of Surgery and Radiotherapy, Medical University of Vienna, Vienna (Austria)
- Departments of Surgery and Radiotherapy, Wiener Neustadt Hospital, Wiener Nuestadt (Austria)
- Departments of Surgery, Radiotherapy and Internal Medicine, Hospital of the Sisters of Mercy, Linz (Austria)
- Departments of Gynaecology and Internal Medicine, Medical University of Graz, Graz (Austria)
- Department of Radiotherapy, St. Johanns-Hospital, Salzburg (Austria)
- Department of Surgery, Hanusch Hospital, Vienna (Austria)
- Department of Surgery, Regional Hospital, Weinviertel Mistelbach (Austria)
- Department of Surgery, Hospital Oberpullendorf, Oberpullendorf (Austria)
- ABCSG Statistics, Vienna (Austria)
Purpose: In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial. Methods and Material: Between January 1996 and June 2004, the Austrian Breast and Colorectal Cancer Study Group (ABCSG) randomly assigned 869 women to receive breast radiotherapy {+-} boost (n 414) or not (n = 417) after breast-conserving surgery (ABCSG Study 8A). Favorable early breast cancer was specified as tumor size <3 cm, Grading 1 or 2, negative lymph nodes, positive estrogen and/or progesterone receptor status, and manageable by breast-conserving surgery. Breast radiotherapy was performed after lumpectomy with 2 tangential opposed breast fields with mean 50 Gy, plus boost in 71% of patients with mean 10 Gy, in a median of 6 weeks. The primary endpoint was local relapse-free survival; further endpoints were contralateral breast cancer, distant metastases, and disease-free and overall survival. The median follow-up was 53.8 months. Results: The mean age was 66 years. Overall, there were 21 local relapses, with 2 relapses in the radiotherapy group (5-y rate 0.4%) vs. 19 in the no-radiotherapy group (5.1%), respectively (p = 0.0001, hazard ratio 10.2). Overall relapses occurred in 30 patients, with 7 events in the radiotherapy group (5-y rate 2.1%) vs. 23 events in the no-radiotherapy group (6.1%) (p = 0.002, hazard ratio 3.5). No significant differences were found for distant metastases and overall survival. Conclusion: Breast radiotherapy {+-} boost in women with favorable early breast cancer after lumpectomy combined with tamoxifen/anastrazole leads to a significant reduction in local and overall relapse.
- OSTI ID:
- 20951648
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 68, Issue 2; Other Information: DOI: 10.1016/j.ijrobp.2006.12.045; PII: S0360-3016(07)00064-8; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Partial breast irradiation as second conservative treatment for local breast cancer recurrence
Accelerated Partial Breast Irradiation for Pure Ductal Carcinoma in Situ